I work with the firms' clients at the intersection of Science, Healthcare and Technology to build value for their innovations through investor relations, corporate communications and media relations programs and strategies.

SciStart creates science-based startup companies. We help entrepreneurs, universities and investors to realize the value of early stage technologies. SciStart has developed a unique solution to solve the growing problem of commercialization of new technologies. Via a mechanism called "startup initiation," we enable tech transfer officers, scientists and entrepreneurs to evaluate, spin off and fund their technologies. In other words, we help bridge the gap between technology and startup creation. This is a community effort that involves interaction among technology owners, subject field experts and other enablers.

Provide C-level investor and public relations counsel for publicly traded and privately held firms in the New England region. Consult with a broad range of early-stage companies in the life science, med-device and cleantech sectors on strategic communications, integrated marketing and startup funding strategies.

Provided strategic media relations and marketing communications to privately held clients in a broad range of industries, as well as investor relations and corporate communications counsel for several publicly traded companies in New England.

Managed the investor and financial media relations efforts for publicly traded and privately held companies for New England’s leading investor relations consultancy. Advised companies in the life sciences, medical device, high technology, telecommunications and industrial capital goods sectors, including three new IPO's. Counseled C-level management on financial disclosure and crisis communications issues. Wrote financial news releases, bylined articles, conference call scripts and annual reports. Handled deal and non-deal road shows and cultivated relationships with institutional investors, sell-side analysts and the financial media.

Provided media relations and corporate communications consultation to a number of high profile financial services clients for one of New England’s leading financial communications agencies. Executed media outreach for senior executives, portfolio managers and analysts in national publications and broadcast media. Provided investor relations counsel to publicly traded clients.

Developed and implemented investor relations and corporate positioning strategies for the firm's publicly traded clients. Identified, qualified and prioritized prospective institutional investors and industry analysts for client companies. Wrote financial disclosure releases, conference call scripts, backgrounders, annual reports and investor communications materials. Managed financial media relations for select companies. Planned and oversaw non-deal investor road-show meetings.

For this international investor relations consultancy, was responsible for marketing the firm’s 200+ publicly traded clients to the New England investment community, including managing non-deal road shows, media tours and investor special events. Directed the investor relations and financial media relations activities of several New England-based, small-cap technology clients.

Thermo Fisher Scientific Inc. (NYSE: TMO), formerly Thermo Electron, is the world leader in serving science, enabling customers to make the world healthier, cleaner and safer. With annual revenues of $10 billion, TMO has more than 30,000 employees and serves over 350,000 customers around the world.Developed corporate communications and investor relations strategies for eight of Thermo’s original "spin-out" companies in the bioinstrumentation, alternative energy, and environmental services markets. Wrote annual and quarterly reports and financial disclosure press releases. Developed communications for more than $550 million in IPO and convertible debt financings, including S-1 filings, materials for bank underwriters and investor road show presentations. Managed financial media relations for subsidiary companies, including media strategies supporting more than $800 million in new corporate acquisitions.